Bridgefront Capital LLC Purchases New Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Bridgefront Capital LLC acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,692 shares of the specialty pharmaceutical company's stock, valued at approximately $204,000.

Other hedge funds also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 4.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after acquiring an additional 30,420 shares during the last quarter. Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 16.4% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock valued at $34,525,000 after buying an additional 88,100 shares during the period. William Blair Investment Management LLC raised its holdings in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock valued at $26,826,000 after buying an additional 10,440 shares during the period. Geode Capital Management LLC raised its holdings in shares of ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock valued at $23,720,000 after buying an additional 3,774 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in ANI Pharmaceuticals by 67.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock worth $17,226,000 after purchasing an additional 125,438 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

Insider Activity

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at $4,048,711.50. The trade was a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares of the company's stock, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock worth $197,792 over the last ninety days. Insiders own 11.10% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. Truist Financial increased their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a report on Monday, April 21st. Guggenheim reissued a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday. HC Wainwright reissued a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, StockNews.com downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded down $1.15 during trading on Wednesday, reaching $60.85. The stock had a trading volume of 263,697 shares, compared to its average volume of 326,591. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $77.00. The stock has a fifty day simple moving average of $66.93 and a two-hundred day simple moving average of $60.74. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -110.64 and a beta of 0.56. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same quarter in the prior year, the firm earned $0.82 EPS. The firm's quarterly revenue was up 43.4% compared to the same quarter last year. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.